Abstract
An increased incidence of colonic cancer is associated with chronic inflammatory bowel disease. Sulphasalazine, metronidazole and more recently, modified forms of 5-aminosalicylic acid are used for maintenance therapy of inflammatory bowel disease. In a series of experiments, we used the 1,2-dimethylhydrazine animal model of colonic cancer in conjunction with these drugs, to study the effect on the development of colon cancer. Inbred male Wistar rats were divided into groups receiving orally: metronidazole 18 mg Kg-1 dy-1; sulphasalazine 60 mg Kg-1 dy-1; 5-aminosalicylic acid 30 and 60 mg Kg-1 dy-1 and olsalazine 60 mg Kg-1 dy-1 administered daily. Half of each group also received weekly injections of DMH 40 mg Kg-1. Metronidazole, sulphasalazine and 30 mg Kg-1 dy-1 5-aminosalicylic acid were co-carcinogenic, increasing either the number of cancers or tumour size. In contrast 60 mg Kg-1 dy-1 5-aminosalicylic acid inhibited tumour size and olsalazine had no effect. These results may have a bearing on long term maintenance therapy in inflammatory bowel disease.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- A-Kareem A. M., Fleiszer D. M., Richards G. K., Senterman M. K., Brown R. A. Effect of long-term metronidazole (MTZ) therapy on experimental colon cancer in rats. J Surg Res. 1984 Jun;36(6):547–552. doi: 10.1016/0022-4804(84)90140-9. [DOI] [PubMed] [Google Scholar]
- Fisher E. R., Paulson J. D., McCoy M. M., 2nd Genesis of 1,2-dimethylhydrazine-induced colon cancer. A light and electron microscopic study. Arch Pathol Lab Med. 1981 Jan;105(1):29–37. [PubMed] [Google Scholar]
- Greenstein A. J., Gennuso R., Sachar D. B., Heimann T., Smith H., Janowitz H. D., Aufses A. H., Jr Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985 Dec 15;56(12):2914–2921. doi: 10.1002/1097-0142(19851215)56:12<2914::aid-cncr2820561232>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- Haagen Nielsen O., Bondesen S. Kinetics of 5-aminosalicylic acid after jejunal instillation in man. Br J Clin Pharmacol. 1983 Dec;16(6):738–740. doi: 10.1111/j.1365-2125.1983.tb02254.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krause J. R., Ayuyang H. Q., Ellis L. D. Occurrence of three cases of carcinoma in individuals with Crohn's disease treated with metronidazole. Am J Gastroenterol. 1985 Dec;80(12):978–982. [PubMed] [Google Scholar]
- Lashner B. A., Heidenreich P. A., Su G. L., Kane S. V., Hanauer S. B. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology. 1989 Aug;97(2):255–259. doi: 10.1016/0016-5085(89)90058-9. [DOI] [PubMed] [Google Scholar]
- Lauritsen K., Hansen J., Ryde M., Rask-Madsen J. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology. 1984 Jun;86(6):1496–1500. [PubMed] [Google Scholar]
- Liu Y. Y., Schmeltz I., Hoffmann D. Chemical studies on tobacco smoke. Quantitative analysis of hydrazine in tobacco and cigarette smoke. Anal Chem. 1974 Jun;46(7):885–889. doi: 10.1021/ac60343a046. [DOI] [PubMed] [Google Scholar]
- McGarrity T. J., Peiffer L. P., Colony P. C. Cellular proliferation in proximal and distal rat colon during 1,2-dimethylhydrazine-induced carcinogenesis. Gastroenterology. 1988 Aug;95(2):343–348. doi: 10.1016/0016-5085(88)90489-1. [DOI] [PubMed] [Google Scholar]
- Meyers S., Sachar D. B., Present D. H., Janowitz H. D. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987 Dec;93(6):1255–1262. doi: 10.1016/0016-5085(87)90253-8. [DOI] [PubMed] [Google Scholar]
- Nauss K. M., Locniskar M., Pavlina T., Newberne P. M. Morphology and distribution of 1,2-dimethylhydrazine dihydrochloride-induced colon tumors and their relationship to gut-associated lymphoid tissue in the rat. J Natl Cancer Inst. 1984 Oct;73(4):915–924. [PubMed] [Google Scholar]
- Rosén A., Ursing B., Alm T., Bárány F., Bergelin I., Ganrot-Norlin K., Hoevels J., Huitfeldt B., Järnerot G., Krause U. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. I. Design and methodologic considerations. Gastroenterology. 1982 Sep;83(3):541–549. [PubMed] [Google Scholar]
- Schröder H., Campbell D. E. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539–551. doi: 10.1002/cpt1972134539. [DOI] [PubMed] [Google Scholar]
- Selhub J., Dhar G. J., Rosenberg I. H. Inhibition of folate enzymes by sulfasalazine. J Clin Invest. 1978 Jan;61(1):221–224. doi: 10.1172/JCI108921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sloan D. A., Fleiszer D. M., Richards G. K., Murray D., Brown R. A. Increased incidence of experimental colon cancer associated with long-term metronidazole therapy. Am J Surg. 1983 Jan;145(1):66–70. doi: 10.1016/0002-9610(83)90168-x. [DOI] [PubMed] [Google Scholar]
- Speck W. T., Stein A. B., Rosenkranz H. S. Mutagenicity of metronidazole: presence of several active metabolites in human urine. J Natl Cancer Inst. 1976 Feb;56(2):283–284. doi: 10.1093/jnci/56.2.283. [DOI] [PubMed] [Google Scholar]
- Sunter J. P., Wright N. A., Appleton D. R. Cell population kinetics in the epithelium of the colon of the male rat. Virchows Arch B Cell Pathol. 1978 Jan 18;26(3):275–287. doi: 10.1007/BF02889556. [DOI] [PubMed] [Google Scholar]
- Toth B. Synthetic and naturally occurring hydrazines as possible cancer causative agents. Cancer Res. 1975 Dec;35(12):3693–3697. [PubMed] [Google Scholar]